iiinova — where your digital self keeps evolving

💼 CARB-X is hiring an ALLIANCE DIRECTOR! We are seeking an expert in infectious disease and AMR-focused in vitro diagnostics who will provide scientific leadership and oversee a diverse portfolio of CARB-X diagnostics projects. #Hiring #IDSky 🧪 ➡️ Apply today! bit.ly/3YLyo5V

000

CARB-X @carb-x.bsky.social · 01/10/2026

CARB-X Alliance Director Betsy Wonderly Trainor will join leaders from across sectors next week at the GO-Dx leadership summit and diagnostic value think tank to continue advancing the GO-Dx compact announced at April’s G7 One Health Summit in France. #IDSky 🧪 🔗 bit.ly/4tBFNlu

000

CARB-X @carb-x.bsky.social · 30/09/2026

This month, CARB-X convened 150+ developers and partners for the annual PD Conference in Lisbon. The conference is one of the business development opportunities available through CARB-X’s Comprehensive Support Model, which gives developers the resources they need to navigate the path to the clinic.

101

Reposted by CARB-X

ESCMID @escmid.bsky.social · 23/09/2026

See the highlights from day 2 of #GAMRIC2026 in our LinkedIn post now live (lnkd.in/p/eicT6B5N) CARB-X LifeArc Global Antibiotic R&D Partnership (GARDP)

151

Reposted by CARB-X

ESCMID @escmid.bsky.social · 24/09/2026

That's a wrap on #GAMRIC2026! See today's highlights over on LinkedIn - lnkd.in/p/e9384VpM Thanks to all who attended and see you next year for #GAMRIC2027 in Bangalore, India. CARB-X LifeArc Global Antibiotic R&D Partnership (GARDP)

121

Reposted by CARB-X

ESCMID @escmid.bsky.social · 24/09/2026

#GAMRIC2026 is officially over and we want to thank all the partners, the programme committee and the attendees who made it such a massive success. We wish you a safe trip home and see you next year in Bangalore, India for #GAMRIC2027! CARB-X LifeArc Global Antibiotic R&D Partnership (GARDP)

121

CARB-X @carb-x.bsky.social · 24/09/2026

The final day of #GAMRIC2026 features important discussions on clinical development, funding, access, and the evolving global AMR landscape. Join Dr. Richard Alm and Dr. Damiano de Felice at the funding for clinical development session at 1 PM WEST. #IDSky 🧪

000

Reposted by CARB-X

ESCMID @escmid.bsky.social · 23/09/2026

Bringing together all aspects of the #AMR research lifecycle is a key benefit of #GAMRIC2026. In the current session, we hear from the different perspectives throughout the lifecycle including IPC, clinical, innovators and trial-design. CARB-X LifeArc Global Antibiotic R&D Partnership (GARDP)

142

CARB-X @carb-x.bsky.social · 23/09/2026

Kevin Outterson takes the stage at #GAMRIC2026 soon to highlight a decade of CARB-X progress and a vision for the future that includes global collaboration to strengthen the AMR innovation ecosystem. #IDSky 🧪

010

CARB-X @carb-x.bsky.social · 23/09/2026

The agenda is packed for day two of #GAMRIC2026! 🔮 10:30 AM WEST: Kevin Outterson speaks about CARB-X 💉 10:45 AM WEST: Richard Alm and Vega Masignani co-chair the prevention session 🦠 1 PM WEST: Decolonization session featuring Trudy Grossman and Christian Groendahl of SNIPR

100

Reposted by CARB-X

ESCMID @escmid.bsky.social · 22/09/2026

Day 1 wrap-up of #GAMRIC2026 is now live on our LinkedIn (lnkd.in/p/e89DW9N3) CARB-X LifeArc Global Antibiotic R&D Partnership (GARDP)

132

Reposted by CARB-X

ESCMID @escmid.bsky.social · 22/09/2026

The second Global AMR Innovators Conference (GAMRIC) has begun! Stay tuned for updates and join the conversation here using #GAMRIC2026. CARB-X LifeArc Global Antibiotic R&D Partnership (GARDP)

162

CARB-X @carb-x.bsky.social · 22/09/2026

CARB-X-supported projects are 5x more likely to reach the clinic than comparable projects outside our portfolio. Why? Because innovation needs more than funding, and the CARB-X Comprehensive Support Model gives developers the expertise and resources needed to navigate this difficult path.

111

CARB-X @carb-x.bsky.social · 22/09/2026

CARB-X is in Lisbon for the first day of #GAMRIC2026! Highlights today: 💡 11 AM WEST: Integrated symposium co-organized by CARB-X and GNA NOW 🧪 Abstracts from CARB-X-supported projects: Till Schäberle of Justus-Liebig-Universität Gießen (JLU) Eric van der Helm of SNIPR Ismael Wayne of the Myers Lab

020

CARB-X @carb-x.bsky.social · 17/09/2026

CARB-X is pleased to support @sniprbiome.com Phase 2a trial for SNIPR001. Through a targeted investment in this study, CARB-X is supporting the generation of proof-of-efficacy data needed to help advance SNIPR001 toward patients. #IDSky 🧪 Read below.

021

CARB-X @carb-x.bsky.social · 16/09/2026

Countdown to #GAMRIC2026: We look forward to joining the global AMR community in Lisbon next week to connect with AMR innovators, explore new research, and exchange ideas on how we can strengthen the AMR innovation ecosystem. See you at GAMRIC! #IDSky 🧪 🔗 Last chance to get tickets: bit.ly/4kE2oKV

000

CARB-X @carb-x.bsky.social · 15/09/2026

110

CARB-X @carb-x.bsky.social · 13/09/2026

CARB-X joins the global sepsis community in recognizing #WorldSepsisDay and this year’s call to “Invest in Sepsis – Save Lives.” Supporting innovative science is essential to develop new ways to prevent infections, detect them early, and provide effective treatment before they become deadly. #IDSky

101

CARB-X @carb-x.bsky.social · 10/09/2026

Dr. Broenstrup’s CARB-X-supported project, a first-in-class small-molecule inhibitor of the S. aureus a-hemolysin, is a Falling Walls Life Sciences Breakthrough of the Year finalist! Since 2020, CARB-X has provided $5.7M in funding and support to the program. Congrats! #IDSky 🧪 🔗 bit.ly/46vNUq2

132

CARB-X @carb-x.bsky.social · 09/09/2026

CARB-X is proud to sponsor #IPNC2026. CARB-X has provided US$65M and scientific support for products to address gonorrhea. Visit our booth at IPNC to learn more. Chief of R&D Richard Alm, PhD, will speak about our gonorrhea portfolio and Portfolio Acceleration Tools. #IDSky 🧪 🔗 bit.ly/4dg6LJn

000

CARB-X @carb-x.bsky.social · 08/09/2026

Congratulations to Vaxdyn on its €11M Series A for a Phase 1 trial for K-VAX, a vaccine candidate against K. pneumoniae and A. baumannii. Since 2020, CARB-X has supported K-VAX with $8.6M in funding and scientific support. #IDSky 🧪 🔗 bit.ly/46e8cEn

000

CARB-X @carb-x.bsky.social · 01/09/2026

📢 CARB-X FUNDING ROUND NEWS! EOIs may be submitted from 10-23 November 2026 to be considered for CARB-X funding for #therapeutics, #preventatives, and #diagnostics. Read the updated FAQs prior to submitting your application. #IDSky #ChemSky 🧪 🔗 bit.ly/4dTKvDj 📩 bit.ly/42hkl

112

CARB-X @carb-x.bsky.social · 31/08/2026

CARB-X is pleased to support LimmaTech Biologics’ Phase 1 trial for LTB-NG6. Since 2024, CARB-X has provided $20M in funding and technical support to advance LTB-NG6 from hit-to-lead to Phase 1. LimmaTech was recently acquired by Eli Lilly and Company. #IDSky 🧪 🔗 bit.ly/4qsAft2

000

CARB-X @carb-x.bsky.social · 24/08/2026

Join CARB-X Executive Director Kevin Outterson at #GAMRIC2026, where he will highlight key milestones and CARB-X's contributions to revitalizing the antibacterial pipeline, and share CARB-X’s vision for the next 10 years. #IDSky 🧪 📅 Sept. 23  ⏰ 10:30 AM – 10:45 AM WEST   🔗 bit.ly/4kE2oKV 

021

CARB-X @carb-x.bsky.social · 20/08/2026

Join CARB-X Alliance Director Betsy Wonderly Trainor at the Next Generation Dx Summit, where she will examine challenges and opportunities in ensuring appropriate use and payment mechanisms to support the successful market entry of new products to address AMR. #IDSky #NGDx 🧪 🔗 bit.ly/4x5B1OZ

000

CARB-X @carb-x.bsky.social · 19/08/2026

New in The Lancet Microbe: CARB-X Executive Director Kevin Outterson co-authored a report on the 2025 workshop convened by the authors in Lagos to help inform the development of the Independent Panel for Evidence for Action Against AMR (IPEA). #IDSky 🧪 🔗 bit.ly/4qlLdk8

110

CARB-X @carb-x.bsky.social · 18/08/2026

A new publication defines a Target Product Profile for new antimicrobials to treat severe bacterial diarrheal disease in children under 5 in LMICs. This is the outcome of a symposium hosted by CARB-X and GNA NOW in 2024 in Porto, Portugal. #IDSky #PedsSky 🧪 🔗 bit.ly/460sfWF

110

CARB-X @carb-x.bsky.social · 12/08/2026

A recent Nature Portfolio publication highlights India’s growing role in AMR R&D and the importance of pairing innovation with patient access. CARB-X is proud to support the development of new therapies from Bugworks and GangaGen, which were featured in the article. #IDSky 🧪 🔗 bit.ly/4hSxT4m

010

CARB-X @carb-x.bsky.social · 10/08/2026

New research from Blacksmith Medicines, supported by CARB-X, highlights a novel class of nonhydroxamate LpxC inhibitors. CARB-X provided $7.2 million in funding and customized support from 2018-2022, advancing this program from lead optimization to preclinical development. #IDSky 🧪 🔗 bit.ly/4q0lEVj

000

CARB-X @carb-x.bsky.social · 05/08/2026

We thank the @senatefinance.bsky.social Subcommittee on Health Care for the thoughtful bipartisan discussion yesterday on antibiotic market failure and the solutions needed to ensure lifesaving antibacterial products continue to be developed and available for patients. #PoliSky 🎥 bit.ly/45D0AuM

120

CARB-X @carb-x.bsky.social · 04/08/2026

CARB-X Executive Director Kevin Outterson will testify today as a witness at a Senate Finance Committee Subcommittee on Health Care Hearing. Antibiotics are essential healthcare infrastructure, yet they remain undervalued and underinvested in. #PoliSky 🎥 bit.ly/45D0AuM

155

Reposted by CARB-X

LifeArc @lifearc.bsky.social · 30/07/2026

Drug-resistant infections are a global challenge. GAMRIC brings together the people developing the solutions. Join the #AMR community in Lisbon this September for three days of discussion, collaboration and new ideas. Register today 👉 gamric.org

142

CARB-X @carb-x.bsky.social · 28/07/2026

📘 New publication! As part of a CARB-X Portfolio Acceleration Tool, a new publication in Clinical Infectious Diseases provides a framework for superiority clinical trials to demonstrate the clinical value of nontraditional antibacterial agents. #IDSky 🧪 🔗 bit.ly/49CR0dU

120

CARB-X @carb-x.bsky.social · 27/07/2026

Congratulations to Trellis Bioscience on its $9M Series C for a Phase 2 trial for TRL1068, a monoclonal antibody treatment for chronic PJI. CARB-X provided $8.9M in funding from 2019-2024, advancing TRL1068 from preclinical development through Phase 1. #IDSky 🧪 🔗 bit.ly/45d1o9v 🩺 bit.ly/4fb4ctE

001

CARB-X @carb-x.bsky.social · 22/07/2026

Congratulations to CARB-X product developer Zeteo Tech, winner of the ADLM Immunology & Infectious Disease Division Abstract Award in Microbiology! Selected from more than 800 submissions, the abstract will be featured at ADLM on July 28. #IDSky 🧪 🔗 Register: bit.ly/4aUEZ4c

020

CARB-X @carb-x.bsky.social · 21/07/2026

📢 LAST CHANCE to submit an abstract to #GAMRIC! Late-breaking abstract submission for #GAMRIC2026 closes tomorrow, July 22 at 12pm CEST. Submit your work before the deadline to be considered. #IDSky 🧪 🔗 Submit now: bit.ly/4dwyHIl

020

CARB-X @carb-x.bsky.social · 20/07/2026

CARB-X is proud to be the push incentive partner for NeoTest, a new @cgdev.org initiative that aims to accelerate the development, commercialization, and adoption of rapid diagnostics for neonatal sepsis in LMICs. #IDSky 🧪 🔗

bit.ly

CARB-X Aims to Accelerate Neonatal Sepsis Diagnostic Development Via Innovative Funding Mechanism | GenomeWeb

Developed by the Center for Global Development, the NeoTest program aims to both push and pull new bloodstream infection tests to market.

131

CARB-X @carb-x.bsky.social · 16/07/2026

Have you registered for #ICID2026? CARB-X is proud to support by sponsoring attendance for researchers from LMICs. CARB-X Chief of R&D Richard Alm is making a presentation at this year’s event. Early registration for the congress ends on July 30 – register now! #IDSky 🧪 🔗 bit.ly/3RpMXM2

010

CARB-X @carb-x.bsky.social · 15/07/2026

CARB-X today announced that Dr. Richard Alm has been appointed Chief of R&D. His scientific leadership and expertise will play a key role in advancing CARB-X's mission of accelerating antibacterial innovation from early development to clinical evaluation. #IDSky 🧪 🔗

bit.ly

CARB-X announces Dr. Richard Alm as next Chief of Research & Development - Carb-X

Dr. Alm to lead CARB-X R&D strategy to accelerate the development of life-saving antibacterial products (BOSTON: July 15, 2026) – Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) today announced that Richard […]

130

CARB-X @carb-x.bsky.social · 14/07/2026

📢 #GAMRIC2026 early registration ends tomorrow! Last chance to register before prices increase. Secure your spot among experts from around the world discussing the future of AMR R&D, economics and policies. CARB-X staff are contributing to multiple sessions. #IDSky 🧪 🔗 bit.ly/4kE2oKV

000

CARB-X @carb-x.bsky.social · 10/07/2026

#GAMRIC2026 is now accepting late-breaking abstracts! Eligible topics are listed at the link below. Submit by July 22, 2026, to be considered to present your work to a global audience working to address AMR. #IDSky 🧪 🔗 Submit here: bit.ly/4dwyHIl

000

CARB-X @carb-x.bsky.social · 08/07/2026

‼️New research in Health Affairs Scholar finds CARB-X-supported projects are nearly 5x more likely to reach clinical development than comparable projects that did not receive CARB-X funding. The study is the first independent, peer-reviewed evaluation of antibacterial incentives. 🔗 bit.ly/3TlmL5J

131

Reposted by CARB-X

ADVANcing Clinical Evidence in Infectious Diseases (ADVANCE-ID) @advance-id.bsky.social · 06/07/2026

Developing innovative rapid diagnostic solutions for Antimicrobial Resistance (AMR)? 🚀 Our Rapid Diagnostics Open Call for AMR is now open! Submit your Expression of Interest at 📋 forms.office.com/r/rt77z5X4fD before 16 August 2026! 🗓️ Find out more at ad-id.co/dt

011

CARB-X @carb-x.bsky.social · 06/07/2026

Congratulations to SNIPR, part of REPhRAME, which received €15M from the European Commission to evaluate the combination of phage therapy and gut microbiome restoration to prevent recurrent UTIs. CARB-X-supported SNIPR001 will be the first step of the treatment strategy. #IDSky 🧪 🔗 bit.ly/4vBvA9P

020

CARB-X @carb-x.bsky.social · 02/07/2026

CARB-X Executive Director Kevin Outterson joined global health experts calling on France to make AMR a strategic health security priority during its G7 presidential year. In Le Monde, they outline four priorities to drive action and innovation. #IDSky 🧪 🔗 bit.ly/4vc44zL 🔗 bit.ly/3SDzPDj

010

CARB-X @carb-x.bsky.social · 01/07/2026

Have you registered for #GAMRIC2026? GAMRIC covers the full spectrum of AMR product development, including scientific, regulatory, policy, and commercial challenges. Register before July 15 early registration deadline and join the global community working to tackle AMR. #IDSky 🧪 🔗 bit.ly/4kE2oKV

010

CARB-X @carb-x.bsky.social · 29/06/2026

In a PharmaVoice article on the rise of NDM-CRE, CARB-X Executive Director Kevin Outterson explains the antibacterial pipeline requires infrastructure-level investment. CARB-X has invested $75M+ in products targeting CRE infections, but more work must be done. #IDSky 🧪 🔗 bit.ly/4gNkr10

020

CARB-X @carb-x.bsky.social · 25/06/2026

CARB-X welcomes FDA approval of Utebzi, the first oral carbapenem approved in the US which may reduce the need for IV therapy. BARDA supported its development for 10+ years, underscoring the sustained investment and collaboration needed to develop innovative antimicrobials. #IDSky 🧪 🔗 bit.ly/4eivk9K

101

CARB-X @carb-x.bsky.social · 17/06/2026

CARB-X is pleased to see Macro Biologics’ Phase 1 trial of Amicidin-β has commenced, a trial co-funded by CARB-X. Since 2017, CARB-X has supported Amicidin-β and helped advance it from preclinical development to Phase 1. We look forward to the progression of this study. #IDSky 🧪 🔗 bit.ly/4eiXqjW

011

CARB-X @carb-x.bsky.social · 16/06/2026

AMR is a global threat, and the response must be global too. CARB-X Investor Day connects product developers, funders, and industry leaders to create opportunities for partnerships and investments that help advance the next generation of innovative antibacterial products. #IDSky 🧪

120